Mizuho Medy

Basic Information

Stock Code
4595
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Saga Prefecture
Establishment Year
November 1977
Listing Year
December 2015
Official Website
https://www.mizuho-m.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Towns, KG Information, Atect, Eiken Chemical, Kainos, Institute of Immunology, Clip, Sysmex, Freedom

Overview

Mizuho Medy is an in vitro diagnostic reagent manufacturer founded in 1977, continuing stable growth in the pharmaceutical industry with influenza test kits as its mainstay.

Current Situation

Mizuho Medy recorded net sales of approximately 11 billion yen and operating profit of approximately 5.1 billion yen for the fiscal year ending December 2023, maintaining a sound financial base. Focusing on the development and manufacturing of in vitro diagnostics, its main products are influenza test kits and pregnancy test kits. It also handles genetic analysis equipment and promotes technological innovation. Based in Kyushu, it has sales offices in Tokyo, Osaka, and Nagoya, building a nationwide sales network. It has strengthened production capacity and R&D through the establishment of a new factory and genetic research institute. It also focuses on environmentally considerate management and contributions to local communities. Aiming for growth after 2025, it has new product development and overseas expansion in view. Although market competition is fierce, it differentiates with its unique in vitro diagnostic technology, meeting the needs of medical sites. It has established internal controls and compliance systems, aiming for sustainable growth.

Trivia

Interesting Facts

  • Grown as a Kyushu-origin specialized in vitro diagnostics manufacturer.
  • Relocated headquarters and factory to Saga Prefecture in 1981 and began manufacturing.
  • Long track record in the domestic market for influenza test kits.
  • Also engaged in in-house development of genetic analysis devices.
  • Diversified with private brand products.
  • History of market change from JASDAQ to Market Second Section.
  • History of strengthening production capacity with new factory opening.
  • Representative Director Fumishige Karukawa is a central figure from the early days of establishment.
  • Uses Deloitte Tohmatsu Limited as external auditor.
  • Contributions to regional revitalization in Saga Prefecture are also highly evaluated.
  • Established presence in Kyushu's pharmaceutical industry.

Hidden Connections

  • Close collaboration with local Saga Prefecture medical sites for product development.
  • Strong relationships with retailers through PB products for drugstores.
  • Introduction of genetic analysis equipment contributes to advanced regional medical care.
  • Supports R&D through device sales to medical research institutions.
  • Strengthened capital ties with local banks including major shareholders.
  • Attention from capital markets due to Tokyo Stock Exchange Standard listing.
  • Production risk dispersion through factory collaboration between Saga and Fukuoka Prefectures.
  • Fosters employee unity with company through employee stock ownership plan.

Future Outlook

Growth Drivers

  • Increased demand for test kits due to aging society.
  • Growing importance of infectious disease testing.
  • Advances in genetic analysis technology and expanding demand.
  • Expansion of drugstore market and PB product growth.
  • Penetration of online medical device sales.
  • Strengthening collaboration with domestic and international medical institutions.
  • Expanded opportunities for new product launches due to regulatory easing.
  • Efficiency gains from DX in the pharmaceutical industry.
  • Promotion of sustainable environmental management.
  • Deepening business development in collaboration with local communities.

Strategic Goals

  • Expand net sales to approx. 15 billion yen.
  • Establish top-class position in Japan in in vitro diagnostics field.
  • Expand product portfolio with new technologies.
  • Full-scale expansion into overseas markets, especially Asia.
  • Reduce environmental impact toward sustainability achievement.
  • Improve business efficiency through in-house DX promotion.
  • Strengthen corporate power through development and utilization of diverse talent.
  • Promote high value-added products and differentiation.
  • Further strengthen regional medical collaboration.
  • Enhance internal controls and compliance systems.

Business Segments

In Vitro Diagnostics Supply for Medical Institutions

Overview
Provides high-accuracy in vitro diagnostic pharmaceuticals and equipment for medical sites.
Competitiveness
Strength in high-sensitivity and rapid diagnostic technology.
Customers
  • Hospitals
  • Clinics
  • Medical offices
  • Public medical institutions
  • Private medical facilities
  • Research institutions
  • University hospitals
  • Clinical testing centers
  • Sanitary inspection offices
  • Medical startups
Products
  • Influenza test reagents
  • Pregnancy test kits
  • Genetic analysis devices
  • Various blood test reagents
  • Infectious disease diagnostic kits
  • Cancer marker test kits
  • Diabetes test kits
  • Allergy test kits
  • Antibody test reagents
  • Molecular diagnostic reagents

Test Kit Supply for Pharmacies and Drugstores

Overview
Provides convenient and reliable test kits for general users.
Competitiveness
Balance of ease of use and high-accuracy test kits.
Customers
  • Nationwide drugstores
  • Compounding pharmacies
  • Drugstores
  • Health consultation counters
  • Health food stores
  • Online pharmacies
  • Regional health centers
  • General retailers
Products
  • Over-the-counter pregnancy test kits
  • Self-diagnostic test kits
  • Lifestyle disease test kits
  • Infectious disease simple test kits
  • Urine test kits
  • Blood sugar measurement reagents
  • Allergy test reagents
  • Excretion test kits

Genetic Analysis Products for R&D Institutions

Overview
Provides specialized products for advanced genetic analysis needs.
Competitiveness
Rapid introduction and customization of cutting-edge technology.
Customers
  • University labs
  • Pharmaceutical company R&D departments
  • Biotechnology companies
  • Public research institutions
  • National Institute of Advanced Industrial Science and Technology
Products
  • High-sensitivity genetic analysis devices
  • PCR reagents
  • Genetic extraction kits
  • Sequencing equipment
  • Reagent delivery systems

OEM/PB Product Manufacturing

Overview
Contract manufactures OEM/PB products according to client needs.
Competitiveness
Quality control and flexible production response.
Customers
  • Drugstore chains
  • Pharmaceutical companies
  • Health equipment manufacturers
  • Retailers
  • Mail-order businesses
Products
  • In vitro diagnostic PB products
  • Test kit OEM manufacturing
  • Health testing related products
  • Brand-specific test kit development

Product Exports for Overseas Markets

Overview
Exports high-quality in vitro diagnostics mainly to Asian countries.
Competitiveness
Reliability compliant with domestic quality standards.
Customers
  • Medical institutions in Asia
  • Overseas importers
  • Global pharmaceutical trading companies
  • Local agents
  • Overseas research institutions
Products
  • In vitro diagnostic pharmaceuticals
  • Test kits
  • Genetic analysis devices
  • Health checkup products

Equipment Maintenance and After-Sales Service

Overview
Provides maintenance and technical support for own products.
Competitiveness
Rapid response and support from specialized staff.
Customers
  • Hospitals
  • Clinics
  • Research institutes
  • Medical equipment sales agents
Products
  • Genetic analysis device maintenance
  • Test equipment support
  • Technical training

Education and Training Services

Overview
Provides educational services to enhance product understanding.
Competitiveness
High-quality education programs by experts.
Customers
  • Medical professionals
  • Technicians
  • Researchers
  • Medical education institutions
Products
  • Test kit handling training
  • Genetic technology education
  • Product application training

Competitive Advantage

Strengths

  • High-specialty in vitro diagnostic technology
  • Regional production base centered in Kyushu
  • Diverse test kit lineup
  • Ownership of in-house developed genetic analysis devices
  • Flexible manufacturing system responsive to customer needs
  • Ensuring high product quality and reliability
  • Stable financial base
  • Private brand product rollout
  • Nationwide sales network
  • Strong legal compliance and internal controls

Competitive Advantages

  • Secures market competitiveness with rapid diagnostic test kits
  • Reliable production sites with manufacturing licenses
  • Differentiation through in-house genetic analysis technology development
  • Distribution network utilizing diverse sales channels
  • Sustainable growth through collaboration with local communities
  • Customer response via customizable OEM system
  • Product competitiveness backed by high-sensitivity technology
  • Product management compliant with latest pharmaceutical regulations
  • Business risk dispersion through multiple bases
  • Continuous technology investment and R&D enhancement

Threats

  • Intense domestic and international pharmaceutical competition
  • Risk of product approval delays due to regulatory strengthening
  • Potential market share reduction from patent expirations
  • Risk of lagging behind competitors in rapid adoption of new technologies
  • Cost increases due to exchange rate fluctuations
  • Demand decline from changes in infectious disease prevalence
  • Price competition pressure from new entrants
  • Legal risks and reputational damage from product defects
  • Challenges in overseas market development
  • Intensifying talent acquisition competition

Innovations

2024: Development of Sensitivity Enhancement Technology for Next-Generation In Vitro Diagnostics

Overview
Introduced ultra-high-sensitivity detection technology to dramatically improve the accuracy of in vitro diagnostics.
Impact
Achieved shortened testing time and increased accuracy, gaining trust in medical settings.

2023: Strengthening In-House Development of Genetic Analysis Devices

Overview
Expanded lineup of device series capable of addressing a wide range of genetic analysis needs.
Impact
Successfully expanded market share in research institutions.

2022: Rapid Development of Novel Coronavirus Test Kits

Overview
Quickly brought test kits to market in response to infectious disease outbreaks.
Impact
Rapid response to social needs, enhancing brand value.

2021: Development of IoT-Integrated Test Equipment

Overview
Developed equipment enabling digital management of test results.
Impact
Contributed to business efficiency in medical settings.

2020: Commercialization of Next-Generation In Vitro Diagnostic Reagents

Overview
Launched new high-accuracy, low-cost reagent series.
Impact
Successfully improved product competitiveness and increased sales.

Sustainability

  • Promoting reduction of environmental impact in manufacturing processes
  • Participation in health promotion activities in collaboration with local communities
  • Formulation of waste recycling rate improvement plans
  • Equipment investment for energy efficiency improvements
  • Strengthening education on employee health and safety
  • Development of environmentally friendly product packaging
  • Setting environmental consideration standards in supply chains
  • Adoption of sustainable procurement policies
  • Funding for local environmental protection activities
  • Publication of highly transparent environmental reports